HER2-Positive Breast Carcinoma

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Neratinib

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Trastuzumab

10 source records aggregated

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Lapatinib

5 source records aggregated

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Afatinib

4 source records aggregated

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Trastuzumab Emtansine

4 source records aggregated

sensitivity

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to Trastuzumab

2 source records aggregated

resistance

Curated

in context · predicts response to

PIK3CA Mutationother → predicts response to Trastuzumab

2 source records aggregated

resistance

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Docetaxel

2 source records aggregated

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Pertuzumab

2 source records aggregated

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Capecitabine

2 source records aggregated

sensitivity

Curated

in context · predicts response to

PIK3CA Mutationother → predicts response to Lapatinib

resistance

Curated

in context · predicts response to

PIK3CA Mutationother → predicts response to Capecitabine

resistance

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Neratinib

sensitivity

Curated

in context · predicts response to

ERBB2 Overexpressionexpression → predicts response to Trastuzumab Emtansine

sensitivity

Curated

in context · predicts response to

BIRC5 Overexpressionexpression → predicts response to Trastuzumab

resistance

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to Everolimus

sensitivity

Curated

in context · predicts response to

PIK3CA Mutationother → predicts response to Everolimus

sensitivity

Curated

in context · predicts response to

PTEN Expressionexpression → predicts response to Fulvestrant

resistance

Curated

in context · predicts response to

PTEN Expressionexpression → predicts response to Everolimus

resistance

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Fulvestrant

sensitivity

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Everolimus

sensitivity

Curated

in context · predicts response to

PIK3CA E545KSNV → predicts response to Trastuzumab

4 source records aggregated

resistance

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Trastuzumab

3 source records aggregated

resistance

Curated

in context · predicts response to

PIK3CA Overexpressionexpression → predicts response to Lapatinib

2 source records aggregated

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Trastuzumab

2 source records aggregated

sensitivity

Curated

in context · predicts response to

PIK3CA E545KSNV → predicts response to Lapatinib

2 source records aggregated

resistance

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Lapatinib

2 source records aggregated

resistance

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Capivasertib

2 source records aggregated

sensitivity

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to PI3Ka/Di

resistance

Curated

in context · predicts response to

PIK3CA K111NSNV → predicts response to PI3Ka/Di

sensitivity

Curated

in context · predicts response to

PIK3CA E545KSNV → predicts response to PI3Ka/Di

sensitivity

Curated

in context · predicts response to

PIK3CA E542KSNV → predicts response to PI3Ka/Di

sensitivity

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to PI-103

sensitivity

Curated

in context · predicts response to

PIK3CA K111NSNV → predicts response to PI-103

sensitivity

Curated

in context · predicts response to

PIK3CA E542KSNV → predicts response to PI-103

sensitivity

Curated

in context · predicts response to

PIK3CA C420RSNV → predicts response to Trastuzumab

resistance

Curated

in context · predicts response to

PTEN Underexpressionexpression → predicts response to Dactolisib

resistance

Curated

in context · predicts response to

PIK3CA K111NSNV → predicts response to Dactolisib

resistance

Curated

in context · predicts response to

PTEN Underexpressionexpression → predicts response to Trastuzumab

resistance

Curated

in context · predicts response to

PIK3CA K111NSNV → predicts response to Trastuzumab

resistance

Curated

in context · predicts response to

PIK3CA Amplificationamplification → predicts response to Dactolisib

sensitivity

Curated

in context · predicts response to

PIK3CA Amplificationamplification → predicts response to Lapatinib

sensitivity

Curated

in context · predicts response to

PIK3CA Overexpressionexpression → predicts response to Trastuzumab

sensitivity

Curated

in context · predicts response to

PIK3CA Overexpressionexpression → predicts response to Dactolisib

sensitivity

Curated

in context · predicts response to

PIK3CA Overexpressionexpression → predicts response to Trastuzumab

resistance

Curated

in context · predicts response to

PIK3CA E542KSNV → predicts response to Pictilisib

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Palbociclib

sensitivity

Curated

in context · predicts response to

PIK3CA Mutationother → predicts response to Capivasertib

sensitivity

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to Trastuzumab

resistance

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to A66

sensitivity

Curated

in context · predicts response to

ERBB4 EXPRESSIONexpression → predicts response to Trastuzumab

resistance

Curated

in context · predicts response to

PIK3CA C420RSNV → predicts response to Pictilisib

sensitivity

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to Pictilisib

sensitivity

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Lapatinib

sensitivity

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Trastuzumab

sensitivity

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to PI3K/BET Inhibitor LY294002

sensitivity

Curated

in context · predicts response to

PTEN Lossdeletion_cna → predicts response to Trastuzumab

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Pictilisib

sensitivity

Curated

in context · predicts response to

PTEN Underexpressionexpression → predicts response to Lapatinib

resistance

Curated

in context · predicts response to

PIK3CA K111NSNV → predicts response to Lapatinib

resistance

Curated

in context · predicts response to

PIK3CA H1047RSNV → predicts response to Pictilisib

sensitivity

Curated

in context · predicts response to

PIK3CA K111NSNV → predicts response to Pictilisib

sensitivity

Curated

in context · predicts response to

PIK3CA E545KSNV → predicts response to Pictilisib

sensitivity

Curated

in context · predicts response to

ERBB2 Amplificationamplification → predicts response to Pilaralisib

sensitivity

Curated

HER2-Positive Breast Carcinoma associated with …ASSOCIATED_WITH11 of 11
← associated with	ERBB2 2 source records aggregated	supports	A	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← associated with	ERBB2 19 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	19	Curated	civic	graph →
← associated with	PIK3CA 4 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
← associated with	PTEN 3 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	3	Curated	civic	graph →
← associated with	BIRC5	supports	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← associated with	PTEN	supports	C	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← associated with	PIK3CA	supports	C	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← associated with	PIK3CA 31 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	31	Curated	civic	graph →
← associated with	PTEN 8 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	8	Curated	civic	graph →
← associated with	ERBB2 4 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
← associated with	ERBB4	supports	D	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →

HER2-Positive Breast Carcinoma associated with …ASSOCIATED_WITH11 of 11

← associated with

ERBB2

2 source records aggregated

supports

Curated

← associated with

ERBB2

19 source records aggregated

supports

Curated

← associated with

PIK3CA

4 source records aggregated

supports

Curated

← associated with

PTEN

3 source records aggregated

supports

Curated

← associated with

BIRC5

supports

Curated

← associated with

PTEN

supports

Curated

← associated with

PIK3CA

supports

Curated

← associated with

PIK3CA

31 source records aggregated

supports

Curated

← associated with

PTEN

8 source records aggregated

supports

Curated

← associated with

ERBB2

4 source records aggregated

supports

Curated

← associated with

ERBB4

supports

Curated

HER2-Positive Breast Carcinoma investigated for …INVESTIGATED_FOR15 of 24show all (up to 200)
← investigated for	Trastuzumabmonoclonal_antibody 2 source records aggregated	supports	A	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Neratinibsmall_molecule	supports	A	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← investigated for	Trastuzumabmonoclonal_antibody 15 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	15	Curated	civic	graph →
← investigated for	Lapatinibsmall_molecule 6 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	6	Curated	civic	graph →
← investigated for	Trastuzumab Emtansineadc 5 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	5	Curated	civic	graph →
← investigated for	Afatinibsmall_molecule 4 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	4	Curated	civic	graph →
← investigated for	Capecitabinesmall_molecule 3 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	3	Curated	civic	graph →
← investigated for	Docetaxelsmall_molecule 2 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Pertuzumabmonoclonal_antibody 2 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Everolimussmall_molecule 2 source records aggregated	supports	B	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Neratinibsmall_molecule	supports	B	HER2-Positive Breast Carcinoma	1	Curated	civic	graph →
← investigated for	Fulvestrantsmall_molecule 2 source records aggregated	supports	C	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Everolimussmall_molecule 2 source records aggregated	supports	C	HER2-Positive Breast Carcinoma	2	Curated	civic	graph →
← investigated for	Trastuzumabmonoclonal_antibody 17 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	17	Curated	civic	graph →
← investigated for	Lapatinibsmall_molecule 9 source records aggregated	supports	D	HER2-Positive Breast Carcinoma	9	Curated	civic	graph →

HER2-Positive Breast Carcinoma investigated for …INVESTIGATED_FOR15 of 24show all (up to 200)

← investigated for

Trastuzumabmonoclonal_antibody

2 source records aggregated

supports

Curated

← investigated for

Neratinibsmall_molecule

supports

Curated

← investigated for

Trastuzumabmonoclonal_antibody

15 source records aggregated

supports

Curated

← investigated for

Lapatinibsmall_molecule

6 source records aggregated

supports

Curated

← investigated for

Trastuzumab Emtansineadc

5 source records aggregated

supports

Curated

← investigated for

Afatinibsmall_molecule

4 source records aggregated

supports

Curated

← investigated for

Capecitabinesmall_molecule

3 source records aggregated

supports

Curated

← investigated for

Docetaxelsmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Pertuzumabmonoclonal_antibody

2 source records aggregated

supports

Curated

← investigated for

Everolimussmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Neratinibsmall_molecule

supports

Curated

← investigated for

Fulvestrantsmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Everolimussmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Trastuzumabmonoclonal_antibody

17 source records aggregated

supports

Curated

← investigated for

Lapatinibsmall_molecule

9 source records aggregated

supports

Curated

HER2-Positive Breast Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 77show all (up to 200)
→ investigated in trials for	Trastuzumabmonoclonal_antibody 116 trials (39 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	116	Observed	clinicaltrials	graph →
→ investigated in trials for	Pertuzumabmonoclonal_antibody 52 trials (28 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	52	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall molecule 34 trials (15 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	34	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall_molecule 28 trials (14 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Trastuzumab Emtansineadc 27 trials (13 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	27	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall_molecule 24 trials (9 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Pyrotinibsmall molecule 24 trials (15 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	24	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 22 trials (4 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Tucatinibsmall_molecule 19 trials (9 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 17 trials (8 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Neratinibsmall_molecule 11 trials (7 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Lapatinibsmall_molecule 10 trials (0 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Epirubicinsmall molecule 9 trials (2 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 9 trials (4 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 8 trials (3 active) · roll-up of the cancer and its descendants	—	—	HER2-Positive Breast Carcinoma	8	Observed	clinicaltrials	graph →

HER2-Positive Breast Carcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 77show all (up to 200)

→ investigated in trials for

Trastuzumabmonoclonal_antibody

116 trials (39 active) · roll-up of the cancer and its descendants

—

116

Observed

→ investigated in trials for

Pertuzumabmonoclonal_antibody

52 trials (28 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Paclitaxelsmall molecule

34 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall_molecule

28 trials (14 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Trastuzumab Emtansineadc

27 trials (13 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Capecitabinesmall_molecule

24 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pyrotinibsmall molecule

24 trials (15 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

22 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tucatinibsmall_molecule

19 trials (9 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

17 trials (8 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Neratinibsmall_molecule

11 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lapatinibsmall_molecule

10 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Epirubicinsmall molecule

9 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Letrozolesmall molecule

9 trials (4 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

8 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

HER2-Positive Breast Carcinoma studied in …STUDIED_INderived10 of 377show all (up to 200)
→ studied in	NCT05132582Phase 3 · active not recruiting A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05880160NA · completed Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07152782Phase 2 · recruiting T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02945579NA · recruiting Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07407920Phase 2 · recruiting Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active)	—	—	Early Stage HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03387553early Phase 1 · completed HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07829900completed First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04585750Phase 1/Phase 2 · recruiting The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05115474Phase 2 · recruiting Study of Screening Brain MRIs in Stage IV Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05378464Phase 1 · suspended Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)	—	—	HER2-Positive Breast Carcinoma	1	Observed	clinicaltrials	graph →

HER2-Positive Breast Carcinoma studied in …STUDIED_INderived10 of 377show all (up to 200)

→ studied in

NCT05132582Phase 3 · active not recruiting

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT05880160NA · completed

Safety of Withdrawal of Pharmacological Treatment for Recovered HER2 Targeted Therapy Related Cardiac Dysfunction · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT07152782Phase 2 · recruiting

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT02945579NA · recruiting

Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active)

—

Observed

Early Stage HER2-Positive Breast Carcinoma

→ studied in

NCT07407920Phase 2 · recruiting

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial · condition mapped ONTOLOGY_EXACT · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT03387553early Phase 1 · completed

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT07829900completed

First-Line Dual Versus Single HER2-Targeted Therapy With Docetaxel for Advanced HER2-Positive Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT04585750Phase 1/Phase 2 · recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT05115474Phase 2 · recruiting

Study of Screening Brain MRIs in Stage IV Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed

→ studied in

NCT05378464Phase 1 · suspended

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer · condition mapped ALIAS · 377 trials mapped (167 active)

—

Observed